MYGN
MYRIAD GENETICS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 28 ▲ Three major passive institutions, Morgan Stanley, Wells Fargo, and U…
- Mar 17 ▲ Myriad Genetics announced FDA approval of its MyChoice® CDx Test as…
- May 14 ▲ 1 insider buy $27.6K at $3.69
- May 27 FDA: Myriad Genetics Highlights Data Showing Broad Clinical Uti…
- Jun 8 ▼ 1 insider sell $66.8K at $4.46
- Jun 23 FDA: Myriad Genetics Expands Availability of Precise MRD™ for C…
- Jul 30 ▼ Myriad Genetics reported Q2 2026 revenue of $190.7M (11% YoY decline…
- Sep 1 ▼ Piper Sandler downgrades
- Sep 16 Leadership: Myriad Genetics Appoints Vishal Sikri Executive Vice Presi…
- Oct 20 ▲ Myriad Genetics (MYGN) has entered into a definitive asset purchase…
- Nov 4 Myriad Genetics reported Q3 2026 revenue of $202.7M, above the $191.…
- Nov 4 ▲ Earnings: MYGN Q3 2026 Earnings: EPS $-0.11 (+46.1% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $27.6K at an average $3.69. 1 insider sold $66.8K. Price is 51% above their cost.
- InstitutionsMIXED
Q3 2026: 25 added (0 new), 25 trimmed or exited.
- AnalystsMIXED
1 of 14 rate it Buy or better. Median target $5.70 (+2%).
- Short sellersSTEADY
Short interest −9.0% to 8.44M shares. 2.0 days to cover, ≈8.8% of shares.
- TrendUPTREND
16% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 30.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $68.6M |
| MACKENZIE FINANCIAL CORP | ADD | $10.8M |
| MARSHALL WACE, LLP | ADD | $8.9M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $7.4M |
| Qube Research & Technologies Ltd | TRIM | $4.7M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $3.4M |
| Jump Financial, LLC | DOUBLED | $3.1M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $3.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is inside the target range. Median implies +2%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 12, 2026 | Stephens & Co. MAINTAIN | Equal-Weight |
| Nov 5, 2026 | TD Cowen MAINTAIN | Hold |
| Nov 5, 2026 | Leerink Partners MAINTAIN | Market Perform |
| Oct 13, 2026 | TD Cowen MAINTAIN | Hold |
| Oct 2, 2026 | Craig-Hallum MAINTAIN | Buy |
| Sep 9, 2026 | UBS MAINTAIN | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Verratti Mark Chief Operating Officer Nov 6, 2026 | AWARD | 146,933 sh |
Sikri Vishal EVP, Commercial Nov 6, 2026 | AWARD | 53,236 sh |
Solaiman Shereen Chief People Officer Nov 6, 2026 | AWARD | 83,049 sh |
Wheeler Benjamin Richard Chief Financial Officer Nov 6, 2026 | AWARD | 121,379 sh |
Fox Jennifer Lynne Chief Legal & Corp Strategy Nov 6, 2026 | AWARD | 139,267 sh |
Muzzey Dale Chief Scientific Officer Nov 6, 2026 | AWARD | 92,632 sh |
Jampa Raj Chief Technology Officer Nov 6, 2026 | AWARD | 58,560 sh |
Fox Jennifer Lynne Chief Legal & Corp Strategy Nov 1, 2026 | AWARD | 39,370 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 3 press releases · 2 bullish · 2 bearish · 1 mixed · 8 neutral- BEARISH SC 13G/ANov 16, 2026
Vestal Point Capital LP filed an amended Schedule 13G for Myriad Genetics Inc, reporting a reduction in beneficial ownership to 0% as of September 30, 2026, down from a prior stake. The filing indicates the fund has fully exited its position in the company.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 9, 2026
Myriad Genetics granted one-time retention stock options to three named executive officers (CFO…
Monitor upcoming quarterly filings for any updates on operational efficiency initiatives and financial performance that these retention awards are tied to. The three-year vesting period suggests…
- NEUTRAL 8-KNov 5, 2026
Myriad Genetics disclosed a cybersecurity incident on November 2, 2026, involving unauthorized…
Monitor subsequent filings for updates on the investigation's findings, any regulatory inquiries (HIPAA, FTC), and potential remediation costs or legal liabilities if patient data was compromised.
- MIXED 8-KNov 4, 2026
Myriad Genetics reported Q3 2026 revenue of $202.7M, above the $191.3M consensus, but GAAP net…
The Prenatal Health sale simplifies the business and provides $210M cash to strengthen the balance sheet, but the core Cancer Care Continuum and Mental Health revenue grew only 1% combined YoY…
All MYGN filing & press-release reports (16)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 9, 2026
- 8-K reportNov 5, 2026
- 8-K reportNov 4, 2026
- INST-CLUSTER reportNov 4, 2026
- SC 13G/A reportOct 27, 2026
- 8-K reportOct 20, 2026
- PRESS-RELEASE reportOct 15, 2026
- 8-K reportOct 9, 2026
- 8-K reportSep 16, 2026
- PRESS-RELEASE reportSep 16, 2026
- PRESS-RELEASE reportJul 30, 2026
- PRESS-RELEASE reportMay 27, 2026
- PRESS-RELEASE reportMar 17, 2026
- INST-CLUSTER reportFeb 28, 2026
- S-3 reportFeb 24, 2026